An Epidemiological Survey of Cachexia in Advanced Cancer Patients and Analysis on Its Diagnostic and Treatment Status

REFERENCES

• Moses AW, Slater C, Preston T, Barber MD, and Fearon KC: Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90, 996–1002, 2004.
   PubMed Web of Science ®Google Scholar
• McClement S: Cancer anorexia-cachexia syndrome: psychological effect on the patient and family. J Wound Ostomy Continence Nurs 32, 264–268, 2005.
   PubMed Web of Science ®Google Scholar
• Hopkinson JB, Wright DN, McDonald JW, and Corner JL: The prevalence of concern about weight loss and change in eating habits in people with advanced cancer. J Pain Symptom Manage 32, 322–331, 2006.
   PubMed Web of Science ®Google Scholar
• Oberholzer R, Hopkinson JB, Baumann K, Omlin A, Kaasa S, et al.: Psychosocial effects of cancer cachexia: A systematic literature search and qualitative analysis. J Pain Symptom Manage 46, 77–95, 2013.
   PubMed Web of Science ®Google Scholar
• Rhondali W, Chisholm GB, Daneshmand M, Allo J, Kang DH, et al.: Association between body image dissatisfaction and weight loss among patients with advanced cancer and their caregivers: a preliminary report. J Pain Symptom Manage 45, 1039–1049, 2013.
   PubMed Web of Science ®Google Scholar
• Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69, 491–497, 1980.
   PubMed Web of Science ®Google Scholar
• Fearon KC, Voss AC, and Hustead DS: Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83, 1345–1350, 2006.
   PubMed Web of Science ®Google Scholar
• Bachmann J1, Büchler MW, Friess H, and Martignoni ME: Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome. Nutr Cancer 65, 827–833, 2013.
   PubMed Web of Science ®Google Scholar
• Wallengren O, Lundholm K, and Bosaeus I: Diagnostic criteria of cancer cachexia: Relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer 21, 1569–1577, 2013.
   PubMed Web of Science ®Google Scholar
• Churm D, Andrew IM, Holden K, Hildreth AJ, and Hawkins C: A questionnaire study of the approach to the anorexia-cachexia syndrome in patients with cancer by staff in a district general hospital. Support Care Cancer 17, 503–507, 2009.
   PubMed Web of Science ®Google Scholar
• Fox KM, Brooks JM, Gandra SR, Markus R, and Chiou CF: Estimation of cachexia among cancer patients based on four definitions. J Oncol 2009, 693458, 2009.
   PubMedGoogle Scholar
• Norton JA, Peacock JL, and Morrison SD: Cancer cachexia. Crit Rev Oncol Hematol 7, 289–327, 1987.
   PubMed Web of Science ®Google Scholar
• Kern KA and Norton JA: Cancer cachexia. JPEN J Parenter Enteral Nutr 12, 286–298, 1988.
   PubMed Web of Science ®Google Scholar
• Tisdale MJ: Pathogenesis of cancer cachexia. J Support Oncol 1, 159–168, 2003.
   PubMedGoogle Scholar
• Argiles JM, Busquets S, Felipe A, and Lopez-Soriano FJ: Muscle wasting in cancer and ageing: Cachexia versus sarcopenia. Adv Gerontol 18, 39–54, 2006.
   PubMedGoogle Scholar
• Argiles JM, Lopez-Soriano FJ, and Busquets S: Mechanisms to explain wasting of muscle and fat in cancer cachexia. Curr Opin Support Palliat Care 1, 293–298, 2007.
   PubMedGoogle Scholar
• Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, et al.: Cachexia: a new definition. Clin Nutr 27, 793–799, 2008.
   PubMed Web of Science ®Google Scholar
• Blum D, Omlin A, Fearon K, Baracos V, Radbruch L, et al.: Evolving classification systems for cancer cachexia: Ready for clinical practice? Support Care Cancer 18, 273–279, 2010.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, et al.: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12, 489–495, 2011.
   PubMed Web of Science ®Google Scholar
• Richards CH, Roxburgh CS, MacMillan MT, Isswiasi S, Robertson EG, et al.: The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PloS One 7, e41883, 2012.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, et al.: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85, 365–376, 1993.
   PubMed Web of Science ®Google Scholar
• The World Health Organization Western Pacific Region, the International Association for the Study of Obesity, and the Intemational Obesity Taskforce: The Asia-Pacifc Perspective: Redefining Obesity and Its Treatment. Melbourne, Australia: Health Communications Australia, 2000.
   Google Scholar
• McKenna RJ, Wellisch D, and Fawzy FI: Rehabilitation and Supportive Care of the Cancer Patient. Atlanta, GA: American Cancer Society, 1995.
   Google Scholar
• Gordon JN, Green SR, and Goggin PM: Cancer cachexia. QJM 98, 779–788, 2005.
   PubMed Web of Science ®Google Scholar
• Ottery FD: Cancer cachexia: Prevention, early diagnosis, and management. Cancer Pract 2, 123–131, 1994.
   PubMedGoogle Scholar
• Segura A, Pardo J, Jara C, Zugazabeitia L, Carulla J, et al.: An epidemiological evaluation of the prevalence of malnutrition in spanish patients with locally advanced or metastatic cancer. Clin Nutr 24, 801–814, 2005.
   PubMed Web of Science ®Google Scholar
• Aslani A, Smith RC, Allen BJ, Pavlakis N, and Levi JA: The predictive value of body protein for chemotherapy-induced toxicity. Cancer 88, 796–803, 2000.
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, et al.: Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13, 3264–3268, 2007.
   PubMed Web of Science ®Google Scholar
• Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, et al.: Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9, 629–635, 2008.
   PubMed Web of Science ®Google Scholar
• Tan BH, Birdsell LA, Martin L, Baracos VE, and Fearon KC: Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15, 6973–6979, 2009.
   PubMed Web of Science ®Google Scholar
• Dalal S, Hui D, Bidaut L, Lem K, Del Fabbro E, et al.: Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: A pilot study. J Pain Symptom Manage 44, 181–191, 2012.
   PubMed Web of Science ®Google Scholar
• Janssen I, Heymsfield SB, Baumgartner RN, and Ross R: Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol 89, 465–471, 2000.
   PubMed Web of Science ®Google Scholar
• Kim J, Wang Z, Heymsfield SB, Baumgartner RN, and Gallagher D: Total-body skeletal muscle mass: Estimation by a new dual-energy x-ray absorptiometry method. Am J Clin Nutr 76, 378–383, 2002.
   PubMed Web of Science ®Google Scholar
• Kullberg J, Brandberg J, Angelhed JE, Frimmel H, Bergelin E, et al.: Whole-body adipose tissue analysis: comparison of MRI, CT and dual energy x-ray absorptiometry. Br J Radiol 82, 123–130, 2009.
   PubMed Web of Science ®Google Scholar
• Prado CM, Birdsell LA, and Baracos VE: The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 3, 269–275, 2009.
   PubMedGoogle Scholar
• Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, et al.: Visceral adipose tissue: relations between single-slice areas and total volume. Am J Clin Nutr 80, 271–278, 2004.
   PubMed Web of Science ®Google Scholar
• Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, et al.: Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97, 2333–2338, 2004.
   PubMed Web of Science ®Google Scholar
• Thibault R and Pichard C: The evaluation of body composition: a useful tool for clinical practice. Ann Nutr Metab 60, 6–16, 2012.
   PubMed Web of Science ®Google Scholar
• Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, et al.: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33, 997–1006, 2008.
   PubMed Web of Science ®Google Scholar
• Kraft M, Kraft K, Gartner S, Mayerle J, Simon P, et al.: L-carnitine-supplementation in advanced pancreatic cancer (carpan)—a randomized multicentre trial. Nutr J 11, 52, 2012.
   PubMed Web of Science ®Google Scholar
• Maccio A, Madeddu C, and Mantovani G: Current pharmacotherapy options for cancer anorexia and cachexia. Expert Opin Pharmacother 13, 2453–2472, 2012.
   PubMed Web of Science ®Google Scholar
• Mondello P1, Mian M, Aloisi C, Famà F, Mondello S, et al.: Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options. Nutr Cancer 67, 12–26, 2015.
   PubMed Web of Science ®Google Scholar
• Cerchietti LC, Navigante AH, Peluffo GD, Diament MJ, Stillitani I, et al.: Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 27, 85–95, 2004.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Maccio A, Madeddu C, Gramignano G, Lusso MR, et al.: A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 15, 1030–1034, 2006.
   PubMed Web of Science ®Google Scholar
• Maccio A, Madeddu C, Gramignano G, Mulas C, Floris C, et al.: A randomized phase iii clinical trial of a combined treatment for cachexia in patients with gynecological cancers: Evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 124, 417–425, 2012.
   PubMed Web of Science ®Google Scholar
• Madeddu C, Dessi M, Panzone F, Serpe R, Antoni G, et al.: Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib +/− megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr 31, 176–182, 2012.
   PubMed Web of Science ®Google Scholar
• Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, et al.: Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54, 540–545, 2005.
   PubMed Web of Science ®Google Scholar
• Wilkes EA, Selby AL, Cole AT, Freeman JG, Rennie MJ, et al.: Poor tolerability of thalidomide in end-stage oesophageal cancer. Eur J Cancer Care (Engl) 20, 593–600, 2011.
   PubMed Web of Science ®Google Scholar
• Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, et al.: Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: Effect on lymphoma growth and on b clinical symptoms. Blood 84, 2472–2479, 1994.
   PubMed Web of Science ®Google Scholar
• Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, et al.: Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89, 2832–2836, 2004.
   PubMed Web of Science ®Google Scholar
• Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D, et al.: Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 98, 300–308, 2008.
   PubMed Web of Science ®Google Scholar
• Lundholm K, Gunnebo L, Korner U, Iresjo BM, Engstrom C, et al.: Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer 116, 2044–2052, 2010.
   PubMed Web of Science ®Google Scholar
• Blum D, Stene GB, Solheim TS, Fayers P, Hjermstad MJ, et al.: Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol 25, 1635–1642, 2014.
   PubMed Web of Science ®Google Scholar